Fig. 3

EGCG inhibits SARS-CoV-2 spike (WT and variants)-mediated infection. a HEK293T-hACE2 and A549-hACE2 cells were treated with the indicated doses of green tea catechins (EGCG, ECG, EGC and EC) for 30 min prior to infection with the pseudovirus bearing SARS-CoV-2 S. b HEK293T-hACE2 cells and A549-hACE2 cells were pre-treated with indicated doses of EGCG for 30 min prior to infection of the pseudovirus bearing SARS-CoV-2 S WT or D614G. GFP fluorescent images were captured by Nikon A1R confocal microscope. c HEK293T-hACE2 cells were incubated with the indicated doses of EGCG for 30 min prior to infection of the pseudovirus bearing SARS-CoV-2 spike with mutations indicated. d HEK293T-hACE2 cells were pretreated with EGCG for 30 min prior to infection of the pseudovirus bearing SARS-CoV-2 S of four newly emerged variants. Cells were lysed and luciferase activity was measured at 48 h post-infection. Viral infectivity was assessed by luciferase activity, which is expressed as a percentage relative to that of the control (untreated). Data are shown as mean ± SD, representative of two independent experiments. ***P < 0.001